COO vs. MMSI: Which Stock Is the Better Value Option?

Zacks analysis favors The Cooper Companies (COO) over Merit Medical (MMSI) for value investors, citing stronger earnings estimate revision activity (Zacks Rank #2 for COO vs #3 for MMSI) and superior valuation metrics. Key comparatives: forward P/E 18.10 (COO) vs 24.27 (MMSI), PEG 1.79 vs 2.39, and P/B 1.77 vs 3.51, resulting in a Value grade of B for COO and C for MMSI. The report concludes COO is the more attractive value pick based on estimate momentum and relative valuation.

Analysis

Market structure: The headline favours larger, well-capitalized device suppliers — COO appears to gain pricing power and share versus smaller niche MMSI given COO’s cheaper forward P/E (18.1) and P/B (1.77) versus MMSI (P/E 24.3, P/B 3.51). Demand signal: steady elective dental/ophthalmic procedures should support revenues over next 1–6 months, tightening supply/demand for higher-quality branded consumables and pressuring lower-scale players. Cross-asset: limited macro bond/FX impact, but expect modestly higher options IV on MMSI and small healthcare defensiveness that can compress corporate credit spreads by 5–15bp in risk-off rallies.

Risk assessment: Tail risks include an adverse FDA label/action or Medicare reimbursement cuts (low-probability, high-impact) that could drop either stock >30% within 3–6 months, and litigation/supply-chain disruption that disproportionately hurts smaller MMSI. Time horizons: immediate (days) = earnings/estimate revisions; short (weeks–months) = analyst upgrades/downgrades and rehabbing guidance; long (quarters–years) = structural adoption, pricing power and potential M&A. Hidden dependencies: hospital capex cycles, single large OEM customers, and disposable raw-material cost swings (PVC/resin) that can swing margins 200–500bps.

Trade implications: Direct play: bias long COO and trim/short MMSI — implement a 6-month asymmetric position: buy COO (2–3% portfolio) vs short MMSI (1–1.5%). Options: 3–6 month 12–20% OTM COO call spreads for leverage; buy 30–45 delta MMSI puts as hedge. Sector rotation: shift 2–4% from small-cap med-dev names into larger defensive med-device (COO, MDT, ABT) over next 30–90 days.

Contrarian angles: Consensus overlooks MMSI’s niche high-margin cath lab and hydration disposables that could re-rate if procedure volumes surprise higher; conversely COO’s premium could compress if growth slips below ~10% YoY. Historical parallels: mid‑2010s device re-ratings show faster re-rating down for overvalued leaders than expected after one missed guide — set guardrails. Unintended consequence: aggressive shorting of MMSI could spur M&A interest, flipping the trade if a buyer emerges within 6–12 months.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in COO (The Cooper Companies) within 2 weeks ahead of the next quarterly report; alternatively use a 6‑month 12–20% OTM call spread sized to 1–1.5% of portfolio; set initial stop-loss at -12% and take-profit at +30–40% or roll on outperformance.
• Implement a dollar‑neutral pair trade: long COO (1.5% portfolio) / short MMSI (1.5% portfolio) for 3–6 months to capture valuation and estimate-revision dispersion; tighten or unwind if spread compresses >15% or if MMSI receives an analyst upgrade to Zacks #1.
• Buy 3–6 month 30–45 delta puts on MMSI sized 0.5–1% of portfolio as downside protection or speculative short; cover if implied volatility spikes >50% or if MMSI reports organic revenue growth >10% QoQ or upgrades to Zacks Rank #2 within 60 days.
• Reduce aggregate exposure to small-cap med‑device names by 2–4% over the next 30 days and redeploy into larger defensive healthcare names (e.g., COO, MDT, ABT) to lower beta; re-evaluate after two fiscal quarters or upon major regulatory/reimbursement announcements.
• Monitor specific catalysts in the next 30–90 days: COO/MMSI earnings dates, any FDA device rulings, and CMS reimbursement notices—take profits or cut positions if a material adverse regulatory bulletin or >15% negative estimate revision occurs.